Faecalibacterium duncaniae as a novel next generation probiotic against influenza

Autor(es):Mostrar menos -

Chollet, Loic ; Heumel, Severine ; Deruyter, Lucie ; Bouilloux, Fabrice ; Delval, Lou ; Robert, Veronique ; Gevaert, Marie-Helene ; Pichavant, Muriel ; Sencio, Valentin ; Robil, Cyril ; Wolowczuk, Isabelle ; Sokol, Harry ; Auger, Sandrine ; Douablin, Alexandre ; Langella, Philippe ; Chatel, Jean-Marc ; Grangette, Corinne ; Trottein, Francois

• Tipo de documento: Artigo Científico
• Fonte: FRONTIERS IN IMMUNOLOGY; v. 15, p. 14-pg., 2024-03-12.

Resumo

The gut-lung axis is critical during viral respiratory infections such as influenza. Gut dysbiosis during infection translates into a massive drop of microbially produced short-chain fatty acids (SCFAs). Among them, butyrate is important during influenza suggesting that microbiome-based therapeutics targeting butyrate might hold promises. The butyrate-producing bacterium Faecalibacterium duncaniae (formerly referred to as F. prausnitzii) is an emerging probiotic with several health-promoting characteristics. To investigate the potential effects of F. duncaniae on influenza outcomes, mice were gavaged with live F. duncaniae (A2-165 or I-4574 strains) five days before infection. Supplementation of F. duncaniae was associated with less severe disease, a lower pulmonary viral load, and lower levels of lung inflammation. F. duncaniae supplementation impacted on gut dysbiosis induced by infection, as assessed by 16S rRNA sequencing. Interestingly, F. duncaniae administration was associated with a recovery in levels of SCFAs (including butyrate) in infected animals. The live form of F. duncaniae was more potent that the pasteurized form in improving influenza outcomes. Lastly, F. duncaniae partially protected against secondary (systemic) bacterial infection. We conclude that F. duncaniae might serve as a novel next generation probiotic against acute viral respiratory diseases. (AU)

• Processo FAPESP: 22/02058-5 - Aspectos clínicos e interações hospedeiro-microbiota em infecção com variantes do SARS-CoV-2 em hamsters
• Beneficiário: Patrícia Brito Rodrigues
• Modalidade de apoio: Bolsas no Exterior - Estágio de Pesquisa - Doutorado
• Processo FAPESP: 18/15313-8 - Análise dos mecanismos moleculares envolvidos na interação de metabólitos da microbiota e células do hospedeiro durante a inflamação
• Beneficiário: Marco Aurélio Ramirez Vinolo
• Modalidade de apoio: Auxílio à Pesquisa - Jovens Pesquisadores - Fase 2
• Processo FAPESP: 19/14342-7 - Comparação do tropismo e patogenicidade da variante gama versus SARS Cov-2 original em camundongos K18-ACE2 humanizado: papel da microbiota intestinal
• Beneficiário: Patrícia Brito Rodrigues
• Modalidade de apoio: Bolsas no Brasil - Doutorado